Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have been given an average rating of “Moderate Buy” by the nine analysts that are presently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $15.75.

Several brokerages have weighed in on VTYX. Oppenheimer lowered their price objective on Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Thursday, June 6th. HC Wainwright reiterated a “neutral” rating and issued a $6.00 price objective on shares of Ventyx Biosciences in a research report on Thursday, June 13th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Ventyx Biosciences by 11.7% in the third quarter. Vanguard Group Inc. now owns 2,662,671 shares of the company’s stock valued at $92,475,000 after acquiring an additional 277,906 shares during the period. Bleakley Financial Group LLC bought a new position in Ventyx Biosciences in the fourth quarter valued at about $81,000. Simplicity Solutions LLC bought a new position in Ventyx Biosciences in the fourth quarter valued at about $81,000. Federated Hermes Inc. bought a new position in Ventyx Biosciences in the fourth quarter valued at about $50,000. Finally, Jump Financial LLC bought a new position in Ventyx Biosciences in the fourth quarter valued at about $72,000. 97.88% of the stock is owned by institutional investors.

Ventyx Biosciences Trading Up 1.7 %

Shares of VTYX opened at $2.95 on Friday. The stock has a 50-day moving average price of $3.22 and a 200-day moving average price of $4.15. Ventyx Biosciences has a 12-month low of $1.87 and a 12-month high of $38.20.

Ventyx Biosciences (NASDAQ:VTYX) last released its earnings results on Thursday, May 9th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.05. During the same period in the prior year, the company posted ($0.68) earnings per share. As a group, research analysts expect that Ventyx Biosciences will post -2.31 earnings per share for the current year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.